Diamondback 360 Peripheral Orbital Atherectomy System
FDA Clearance Information
The Diamondback 360 Peripheral Orbital Atherectomy System was cleared by the FDA via the 510(k) pathway on February 28, 2014. It is manufactured by Cardiovascular Systems and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- Treatment of stenotic peripheral arteries with the intent to facilitate revascularization.
- Treatment of calcified lesions in peripheral arteries by plaque modification using orbital atherectomy.
- Use in peripheral arterial vessels appropriate for the specific catheter size and labeled device configuration.
Clinical Applications
- Plaque modification before balloon angioplasty in calcified peripheral arterial disease.
- Treatment preparation for stenotic lesions in lower-extremity peripheral arteries.
- Facilitation of peripheral arterial revascularization when calcium limits balloon expansion or device passage.
- Use during endovascular treatment of peripheral arterial lesions selected according to the device labeling.
Reported off-label uses
- Use in coronary arteries or other vascular beds outside the labeled peripheral indication may be described in clinical practice for orbital atherectomy devices, but it is not an on-label use of this peripheral system.
Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The system includes a specialized atherectomy catheter and drive unit; catheter diameter, guidewire requirements, and treated-vessel size depend on the specific configuration.
- The catheter is advanced over a compatible guidewire under fluoroscopic imaging, and the operator uses short treatment runs with saline infusion according to the instructions for use.
- Potential complications include vessel dissection or perforation, thrombosis, distal embolization, spasm, bleeding, and access-site complications.
- It is not a replacement for all forms of revascularization; medication, balloon angioplasty, stenting, bypass surgery, or other atherectomy techniques may be appropriate depending on the lesion.
- MRI safety depends on the exact catheter and system components and their condition. The device should not be assumed to be MRI safe; consult the current manufacturer labeling before MRI.
Linked Studies (19)
Coronary Intra-orbital Atherectomy Complications and Procedural Failure: Insight From the Manufacturer and User Facility Device Experience (MAUDE) Database.
Cureus
RCT|prospective|retrospective|case Series|other View Source →Initial experience with orbital atherectomy in a tertiary centre in the Netherlands.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
RCT|prospective|retrospective|case Series|other View Source →Japan-USA Orbital Atherectomy for Calcific Coronary Lesions: COAST Study, Harmonization by Doing Proof-of-Concept.
Cardiovascular revascularization medicine : including molecular interventions
RCT|prospective|retrospective|case Series|other View Source →Coronary orbital atherectomy using a five-French guiding catheter.
Cardiovascular intervention and therapeutics
View Source →Is crossability of the classic crown with the glide assist superior to the micro crown in the Diamondback 360® coronary orbital atherectomy system?
Cardiovascular intervention and therapeutics
RCT|prospective|retrospective|case Series|other View Source →Orbital atherectomy for calcified femoropopliteal lesions: a current review.
The Journal of cardiovascular surgery
View Source →Iliofemoral peripheral orbital atherectomy for optimizing TAVR access: An innovative strategy in the absence of alternative access options.
Cardiovascular revascularization medicine : including molecular interventions
RCT|prospective|retrospective|case Series|other View Source →Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial.
Cardiovascular revascularization medicine : including molecular interventions
RCT|prospective|retrospective|case Series|other View Source →The potential cost-effectiveness of the Diamondback 360® Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach.
Therapeutic advances in cardiovascular disease
RCT|prospective|retrospective|case Series|other View Source →Quantification by optical coherence tomography imaging of the ablation volume obtained with the Orbital Atherectomy System in calcified coronary lesions.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
RCT|prospective|retrospective|case Series|other View Source →Critical hand ischemia treatment via orbital atherectomy-A single center observational retrospective analysis.
Cardiovascular revascularization medicine : including molecular interventions
RCT|prospective|retrospective|case Series|other View Source →Evaluation of the Diamondback 360 Coronary Orbital Atherectomy System for treating de novo, severely calcified lesions.
Expert review of medical devices
RCT|prospective|retrospective|case Series|other View Source →Orbital Atherectomy for Treating De Novo Severely Calcified Coronary Narrowing (1-Year Results from the Pivotal ORBIT II Trial).
The American journal of cardiology
View Source →Orbital atherectomy: device evolution and clinical data.
The Journal of invasive cardiology
RCT|prospective|retrospective|case Series|other View Source →Cost-effectiveness analysis of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in subjects with calcified femoropopliteal lesions.
ClinicoEconomics and outcomes research : CEOR
RCT|prospective|retrospective|case Series|other View Source →Orbital atherectomy for symptomatic lower extremity disease.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
RCT|prospective|retrospective|case Series|other View Source →Optimal techniques with the Diamondback 360° System achieve effective results for the treatment of peripheral arterial disease.
Journal of cardiovascular translational research
RCT|prospective|retrospective|case Series|other View Source →Use and abuse of atherectomy: where should it be used?
Seminars in vascular surgery
RCT|prospective|retrospective|case Series|other View Source →Treatment of lower extremity vascular disease: the Diamondback 360 degrees Orbital Atherectomy System.
Expert review of medical devices
RCT|prospective|retrospective|case Series|other View Source →Frequently Asked Questions
What are the clinical indications for Diamondback 360 Peripheral Orbital Atherectomy System?
The device is indicated for plaque modification in peripheral arterial disease, particularly in cases with significant arterial calcification.
What outcomes have been reported in clinical studies?
Studies have reported effective revascularization and improved procedural access, particularly for TAVR, using the device.
What complications have been reported?
Safety data indicate guidewire fractures as a potential complication during procedures involving the device.